Is it a Wise Decision to Keep Your Bio-Techne (TECH) Position?

Aristotle Capital Management, an independent/employee-owned investment management organization, published its “Aristotle Core Equity” first quarter 2022 investor letter – a copy of which can be downloaded here. For the first quarter of 2022, Aristotle Atlantic’s Core Equity Composite posted a total return of -6.79% gross of fees (-6.89% net of fees), underperforming the S&P 500 Index, which recorded a total return of -4.60%. Try to spend some time looking at the fund’s top 5 holdings to be informed about their best picks for 2022.

In its Q1 2022 investor letter, Aristotle Capital Management Core Equity Fund mentioned Bio-Techne Corporation (NASDAQ:TECH) and explained its insights for the company. Founded in (year founded), Bio-Techne Corporation (NASDAQ:TECH) is a Minneapolis, Minnesota-based biotech company with a $15.1 billion market capitalization. Bio-Techne Corporation (NASDAQ:TECH) delivered a -25.28% return since the beginning of the year, while its 12-month returns are down by -6.59%. The stock closed at $386.56 per share on May 27, 2022.

Here is what Aristotle Capital Management Small Cap Equity has to say about Bio-Techne Corporation (NASDAQ:TECH) in its Q1 2022 investor letter:

Bio-Techne underperformed in the first quarter following a strong performance in 2021. We believe the pullback in the first quarter was largely due to the broader market sentiment and weakness in high-growth, high-valuations names than anything fundamental to Bio-Techne. In fact, the company continues to enjoy strong end markets and healthy biopharma R&D spending.”

Countries With Highest Medical Research Spending

Likoper/Shutterstock.com

Our calculations show that Bio-Techne Corporation (NASDAQ:TECH) fell short and didn’t make it on our list of the 30 Most Popular Stocks Among Hedge Funds. Bio-Techne Corporation (NASDAQ:TECH) was in 29 hedge fund portfolios at the end of the first quarter of 2022, compared to 24 funds in the previous quarter. Bio-Techne Corporation (NASDAQ:TECH) delivered a -7.83% return in the past 3 months.

In November 2021, we also shared another hedge fund’s views on Bio-Techne Corporation (NASDAQ:TECH) in another article. You can find other investor letters from hedge funds and prominent investors on our hedge fund investor letters 2022 Q1 page.

Disclosure: None. This article is originally published at Insider Monkey.